Research Activity
AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival
Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles
Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability
FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies
AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
Cancer research, AACR 2025, Marengo Therapeutics, BriaCell, oncology advancements, colorectal cancer, breast cancer, immunotherapy
Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027
Financial savings, Pfizer, Financial cost, Pfizer
Roche’s WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25
Roche, WRN inhibitor, MSI-H tumors, AACR25, cancer research, oncology
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending
United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher
Versant’s Granite Bio unveils with $100M for new autoimmune disease antibodies
Autoimmune Diseases, granite, GRT-001, Versant, interleukin-3
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
Ataxia, Spinocerebellar, Stemchymal, Machado-Joseph Disease, Spinocerebellar, Ataxia, Mesenchymal Stem Cells
Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme
Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting